22 men with metastatic breast cancer were treated with endocrine therapy. All 22 patients were initially treated by bilateral orchiectomy, and objective response was seen in 11 (50%) patients for 15 months. Bilateral adrenalectomy was performed subsequently in 10 patients, and 8 (80%) patients had a
Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients
โ Scribed by Ann M. Dnistrian; Morton K. Schwartz; Alfred A. Fracchia; Richard J. Kaufman; Thomas B. Hakes; Violante E. Currie
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- English
- Weight
- 416 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Tamoxifen has proven to be beneficial in the chemoprevention of breast cancer in women at increased risk for the disease. Other compounds that mediate the estrogen pathway remain to be tested for clinical efficacy. The mechanism of action, efficacy, and dose response of the estrogen modulators is de
The dose of adjuvant chemotherapy for breast cancer may be an important factor in the success of the treatment program. In a retrospective analysis, the authors determined whether patients who were irradiated either postoperatively (N = 29) or as part of primary treatment (N = 13) received a lower d
This study compared the effectiveness of two psychological treatments in a group of 57 patients with various types of cancer attending the Royal Marsden Hospital. Patients referred for psychiatric assessment who met criteria for an abnormal adjustment reaction were randomly allocated to either 8 wee
This review presents our experience with the use of estrogen receptors (ER) and progesterone receptors (PgR) in the prediction of response to endocrine therapy in stage IV breast cancer. Presence of ER (>3 fmoUmg cytosol protein) significantly predicted response to the antiestrogen tamoxifen and to